Aeglea BioTherapeutics, Inc. announced the appointment of Cameron Turtle, DPhil as Chief Executive Officer (CEO) and member of the Board of Directors. Prior to his appointment as CEO, Dr. Turtle was the Chief Operating Officer of Spyre and previously served as the Chief Strategy Officer of BridgeBio Pharma, Inc. and Chief Business Officer of Eidos Therapeutics, Inc.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.38 USD | -4.86% | +13.20% | +73.70% |
May. 15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
May. 13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+73.70% | 1.51B | |
+7.52% | 113B | |
+11.38% | 106B | |
+0.82% | 22.27B | |
-12.64% | 22.22B | |
-4.59% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+7.77% | 14.29B | |
+37.41% | 12.52B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Aeglea BioTherapeutics, Inc. Appoints Cameron Turtle as Chief Executive Officer